Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 5Breast 4Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Weight Loss 1Vomiting 1Nausea 1Melanoma 1Anorexia 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Palonosetron × Dermatologic × Clear all
NCT00412425 2012-05-04

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 4 charts
Dermatologic

Anorexia, Melanoma, Nausea, Vomiting, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡